Financial Results, Approved Share Repurchase Programs, and Reported Best Practices - Research Report on Walgreen, AmerisourceBergen, Cardinal Health, Rite Aid, and Omnicare PR Newswire NEW YORK, August 20, 2013 NEW YORK, August 20, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Walgreen Co. (NYSE: WAG), AmerisourceBergen Corporation (NYSE: ABC), Cardinal Health, Inc. (NYSE: CAH), Rite Aid Corp. (NYSE: RAD), and Omnicare Inc. (NYSE: OCR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Walgreen Co. Research Report On August 14, 2013, Walgreen Co. (Walgreens) reported that Alex Gourlay, Chief Executive of the Health & Beauty Division, Alliance Boots, has been appointed Walgreens Executive Vice President, President of Customer Experience and Daily Living, with effect from October 1, 2013. Walgreens stated that Mr. Gourlay will report to Greg Wasson (Walgreens President and CEO) and in his new role Gourlay will spearhead Walgreens Daily Living business operations. Mr. Wasson commented, "At Walgreens, Alex will lead a strong Daily Living business team - which is already building momentum - to further advance our vision to be the first choice in health and daily living for everyone in America, and beyond. In the future, you can expect to hear about additional moves by both organizations to further support the combination of our two iconic brands." The Full Research Report on Walgreen Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/844c_WAG ] -- AmerisourceBergen Corporation Research Report On August 8, 2013, AmerisourceBergen Corporation (AmerisourceBergen) reported that its Board of Directors has approved a new $750 million share repurchase program. According to the Company, it has $446.1 million remaining related to its prior November 2012 authorization, which brings the total amount authorized for repurchases to $1.2 billion. Amerisource Bergen further stated that, during FY 2013 (period ending September 30, 2013), AmerisourceBergen spent $401.1 million to repurchase its outstanding shares of common stock. Steven H. Collis, AmerisourceBergen President & CEO, commented, "Our share repurchases during fiscal year 2013 and our new program demonstrate our continued commitment to delivering long-term shareholder value. While our expectations for share repurchases over the next few quarters have not changed, the new authorization gives us significant longer-term flexibility." The Company also informed that its Board of Directors approved a cash dividend of $0.21 per share on Common Stock, payable on September 3, 2013, to stockholders of record at the close of business on August 19, 2013. The Full Research Report on AmerisourceBergen Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/29fb_ABC ] -- Cardinal Health, Inc. Research Report On August 14, 2013, Cardinal Health, Inc. (Cardinal Health) launched a unique publication entitled Independent Pharmacy Best Practices Guide: Innovating Independents at its yearly Retail Business Conference (RBC) for independent pharmacies. According to Cardinal Health, the report showcased 14 unique programs that are executed by independent pharmacists all over the United States to improve patient care and drive business results. Steve Lawrence, Senior Vice President of Independent Sales for Cardinal Health, commented, "The independent pharmacists we serve are always striving to provide high-quality, personalized care to patients while positioning their businesses to succeed. We're delighted to honor this year's winner and finalists by sharing their best practices at RBC 2013, and we congratulate them for their commitment to community pharmacy excellence." The Full Research Report on Cardinal Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ee30_CAH ] -- Rite Aid Corp. Research Report On August 15, 2013, Rite Aid Corp. (Rite Aid) reported that customers can now receive seasonal flu shots at all Rite Aid pharmacies nationwide. The Company stated that the interested customers can go to any of more than 4,600 Rite Aid pharmacies for their flu shots (covered by most insurance plans including Medicare Part B, from a Rite Aid certified immunizing pharmacist, subject to state regulations). According to the Company, flu shots are given during pharmacy hours without any prior appointments. Robert I. Thompson, Rite Aid Executive Vice President of Pharmacy commented, "While it's too early to tell what the 2013-2014 flu season will bring, it's not too early to visit your Rite Aid pharmacist for a flu shot. Getting a flu shot as soon as it is available remains the single best way to protect yourself and others against the flu." The Full Research Report on Rite Aid Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/f64e_RAD ] -- Omnicare Inc. Research Report On July 24, 2013, Omnicare Inc. (Omnicare) declared its Q2 2013 financial results. Net sales stood at $1.6 billion up 2.2% YoY, while gross profit for the quarter was $378.5 million compared to $367.3 million in Q2 2012. GAAP earnings per diluted share was $0.48, versus $0.17 in Q2 2012. Adjusted EBITDA stood at $179 million and cash flows from operations stood at $154 million in Q2 2013, compared to $170 million and $120 million, respectively, in Q2 2012. Nitin Sahney, Omnicare's President and CEO, stated, "For the first time in six quarters, we generated net organic bed growth in our Long-Term Care Group - a trend we believe will be sustainable. We believe these key operational advancements reinforce Omnicare's efforts to build upon a foundation that will enable us to better leverage our growth platforms." For full-year FY 2013, Omnicare expects revenue to be within $6.1 billion to $6.3 billion range. The Full Research Report on Omnicare Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ef9e_OCR ] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Financial Results, Approved Share Repurchase Programs, and Reported Best Practices - Research Report on Walgreen,
Press spacebar to pause and continue. Press esc to stop.